These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

981 related articles for article (PubMed ID: 21270815)

  • 1. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
    Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
    Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm.
    Konda T; Enomoto A; Aritomi S; Niinuma K; Koganei H; Ogawa T; Nitta K
    Am J Nephrol; 2009; 30(2):155-61. PubMed ID: 19325231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
    Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
    Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
    Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
    Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
    Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
    Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel.
    Shimizu H; Nakagami H; Yasumasa N; Mariana OK; Kyutoku M; Koriyama H; Nakagami F; Shimamura M; Rakugi H; Morishita R
    Hypertens Res; 2012 Jan; 35(1):77-81. PubMed ID: 21881574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine.
    Toba H; Nakagawa Y; Miki S; Shimizu T; Yoshimura A; Inoue R; Asayama J; Kobara M; Nakata T
    Hypertens Res; 2005 Aug; 28(8):689-700. PubMed ID: 16392774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
    Baylis C; Qiu C; Engels K
    Am J Kidney Dis; 2001 Dec; 38(6):1292-7. PubMed ID: 11728963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
    Fan YY; Kohno M; Nakano D; Ohsaki H; Kobori H; Suwarni D; Ohashi N; Hitomi H; Asanuma K; Noma T; Tomino Y; Fujita T; Nishiyama A
    J Hypertens; 2010 May; 28(5):1034-43. PubMed ID: 20411599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
    Ohishi M; Takagi T; Ito N; Terai M; Tatara Y; Hayashi N; Shiota A; Katsuya T; Rakugi H; Ogihara T
    Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.
    Takatsu M; Hattori T; Murase T; Ohtake M; Kato M; Nashima K; Nakashima C; Takahashi K; Ito H; Niinuma K; Aritomi S; Murohara T; Nagata K
    J Hypertens; 2012 Sep; 30(9):1845-55. PubMed ID: 22796710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker.
    Konoshita T; Makino Y; Kimura T; Fujii M; Wakahara S; Arakawa K; Inoki I; Nakamura H; Miyamori I;
    J Hypertens; 2010 Oct; 28(10):2156-60. PubMed ID: 20625317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats.
    Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Nako H; Ogawa H; Kim-Mitsuyama S
    J Hypertens; 2010 Jun; 28(6):1321-9. PubMed ID: 20224431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.
    Takashima K; Nishiyama C; Arisaka N; Takahashi T; Souma S; Tsuda M; Hayashi M; Kasahara H; Kodama H; Tamura T; Murakami M; Kuroda J; Sato F
    Arzneimittelforschung; 2009; 59(2):79-85. PubMed ID: 19338138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
    Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
    Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T;
    Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
    Morimoto S; Yano Y; Maki K; Iwasaka T
    J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of N-type Ca(2+) channels in the fibrotic process of the kidney in rats.
    Mishima K; Maeshima A; Miya M; Sakurai N; Ikeuchi H; Hiromura K; Nojima Y
    Am J Physiol Renal Physiol; 2013 Mar; 304(6):F665-73. PubMed ID: 23324177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.